HCA Healthcare, Inc. $HCA Shares Sold by Te Ahumairangi Investment Management Ltd

Te Ahumairangi Investment Management Ltd lowered its position in HCA Healthcare, Inc. (NYSE:HCA) by 20.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,832 shares of the company’s stock after selling 2,809 shares during the quarter. Te Ahumairangi Investment Management Ltd’s holdings in HCA Healthcare were worth $5,057,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HCA. Capital World Investors grew its position in shares of HCA Healthcare by 0.8% in the fourth quarter. Capital World Investors now owns 4,999,422 shares of the company’s stock valued at $2,334,040,000 after purchasing an additional 40,086 shares during the last quarter. Geode Capital Management LLC grew its holdings in HCA Healthcare by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 3,663,705 shares of the company’s stock valued at $1,702,738,000 after buying an additional 13,565 shares during the last quarter. Norges Bank acquired a new position in shares of HCA Healthcare in the fourth quarter worth $1,262,513,000. Arrowstreet Capital Limited Partnership boosted its stake in shares of HCA Healthcare by 1.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,065,225 shares of the company’s stock valued at $880,199,000 after acquiring an additional 36,414 shares during the last quarter. Finally, Viking Global Investors LP raised its stake in HCA Healthcare by 58.5% in the 2nd quarter. Viking Global Investors LP now owns 1,872,133 shares of the company’s stock valued at $717,214,000 after purchasing an additional 690,773 shares during the last quarter. Institutional investors and hedge funds own 62.73% of the company’s stock.

HCA Healthcare Trading Up 1.2%

Shares of HCA Healthcare stock opened at $377.81 on Friday. The business’s fifty day moving average price is $431.36 and its 200 day moving average price is $474.09. The stock has a market capitalization of $83.81 billion, a P/E ratio of 12.99, a PEG ratio of 1.18 and a beta of 1.12. HCA Healthcare, Inc. has a twelve month low of $330.00 and a twelve month high of $556.52.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings data on Friday, April 24th. The company reported $7.15 earnings per share for the quarter, missing the consensus estimate of $7.19 by ($0.04). The firm had revenue of $19.11 billion during the quarter, compared to analyst estimates of $19.09 billion. HCA Healthcare had a net margin of 8.89% and a negative return on equity of 295.93%. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same period in the prior year, the firm earned $6.45 earnings per share. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. As a group, sell-side analysts predict that HCA Healthcare, Inc. will post 30.07 EPS for the current year.

HCA Healthcare Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 16th will be given a $0.78 dividend. The ex-dividend date of this dividend is Tuesday, June 16th. This represents a $3.12 annualized dividend and a yield of 0.8%. HCA Healthcare’s dividend payout ratio (DPR) is 10.73%.

Wall Street Analysts Forecast Growth

HCA has been the subject of a number of analyst reports. Argus cut their price objective on shares of HCA Healthcare from $560.00 to $500.00 and set a “buy” rating for the company in a research report on Monday, May 4th. Deutsche Bank Aktiengesellschaft cut their price target on HCA Healthcare from $558.00 to $540.00 and set a “buy” rating for the company in a report on Tuesday, April 28th. TD Cowen decreased their price objective on HCA Healthcare from $561.00 to $500.00 and set a “buy” rating on the stock in a report on Monday, April 27th. UBS Group increased their target price on HCA Healthcare from $598.00 to $635.00 and gave the stock a “buy” rating in a research report on Monday, February 23rd. Finally, Leerink Partners dropped their price objective on shares of HCA Healthcare from $573.00 to $500.00 and set an “outperform” rating for the company in a research note on Monday, April 27th. Fifteen investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $506.14.

About HCA Healthcare

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.